High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT

2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03130582

Enrollment

Registered

2017-04-26

Start date

2005-11-30

Completion date

2016-12-31

Last updated

2017-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

high-dose etoposide,autologous peripheral blood stem cell transplantation

Brief summary

patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2\*108/kg for mononuclear cells and/or 2\*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT

Interventions

DRUGhigh-dose etoposide

an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 60 Years

Healthy volunteers

Inclusion criteria

* relapsed/refractory lymphoma ,siut APBSCT

Exclusion criteria

* bone marrow without involvement by lymphoma cells

Design outcomes

Primary

Measure	Time frame	Description
death	10 years	death
CR	10 years	Complete response
relapse	10 years	relapse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026